(CAMT) Camtek - Overview
Stock: Inspection, Metrology, Semiconductor, Wafer, Packaging
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 57.9% |
| Relative Tail Risk | -3.88% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.02 |
| Alpha | 39.46 |
| Character TTM | |
|---|---|
| Beta | 1.881 |
| Beta Downside | 1.813 |
| Drawdowns 3y | |
|---|---|
| Max DD | 63.16% |
| CAGR/Max DD | 1.19 |
Description: CAMT Camtek January 10, 2026
Camtek Ltd. (NASDAQ: CAMT) designs, manufactures, and sells a broad portfolio of inspection and metrology systems for the semiconductor supply chain, covering advanced packaging, wafer-level packaging, and panel inspection. Its product line includes the Hawk platform for advanced packaging, the Eagle series (G5, i, AP) that combine 2-D/3-D inspection and metrology, and the Golden Eagle system for fan-out wafer-level packaging with deep-learning-driven defect classification. The company also offers a suite of MicroProf tools (AP, DI, FE, FS, PT, MHU, TL, 200, 300) that serve wafer metrology, optical inspection, and hybrid metrology needs across semiconductors, MEMS, sapphire, and LED markets.
Key recent metrics (FY 2023) show revenue of roughly $120 million, up about 8 % year-over-year, with a gross margin near 45 % and an operating cash-flow conversion rate of 70 %. Camtek’s backlog has risen to ~ $200 million, reflecting strong demand from advanced-packaging customers such as TSMC and Samsung, which are expanding 3-D-IC and fan-out-on-panel production at a projected 15 % CAGR through 2028. The broader semiconductor equipment sector is being driven by AI-chip demand, the U.S. CHIPS Act incentives, and a shift toward diversified, on-shoring supply chains-factors that could boost Camtek’s addressable market.
For a deeper, data-driven assessment of Camtek’s valuation and risk profile, you may find the analysis on ValueRay worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 47.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.64 > 1.0 |
| NWC/Revenue: 161.0% < 20% (prev 121.5%; Δ 39.52% < -1%) |
| CFO/TA 0.10 > 3% & CFO 122.2m > Net Income 47.8m |
| Net Debt (319.4m) to EBITDA (157.0m): 2.03 < 3 |
| Current Ratio: 7.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.8m) vs 12m ago -7.45% < -2% |
| Gross Margin: 50.36% > 18% (prev 0.48%; Δ 4988 % > 0.5%) |
| Asset Turnover: 46.83% > 50% (prev 47.61%; Δ -0.79% > 0%) |
| Interest Coverage Ratio: 743.2 > 6 (EBITDA TTM 157.0m / Interest Expense TTM 37.0k) |
Altman Z'' 5.84
| A: 0.63 (Total Current Assets 899.8m - Total Current Liabilities 118.7m) / Total Assets 1.23b |
| B: 0.28 (Retained Earnings 350.6m / Total Assets 1.23b) |
| C: 0.03 (EBIT TTM 27.5m / Avg Total Assets 1.04b) |
| D: 0.54 (Book Value of Equity 352.3m / Total Liabilities 653.0m) |
| Altman-Z'' Score: 5.84 = AAA |
Beneish M -2.76
| DSRI: 1.31 (Receivables 112.5m/70.7m, Revenue 485.2m/400.6m) |
| GMI: 0.95 (GM 50.36% / 47.83%) |
| AQI: 0.95 (AQ_t 0.22 / AQ_t-1 0.23) |
| SGI: 1.21 (Revenue 485.2m / 400.6m) |
| TATA: -0.06 (NI 47.8m - CFO 122.2m) / TA 1.23b) |
| Beneish M-Score: -2.76 (Cap -4..+1) = A |
What is the price of CAMT shares?
Over the past week, the price has changed by +2.02%, over one month by +34.93%, over three months by +18.14% and over the past year by +61.11%.
Is CAMT a buy, sell or hold?
- StrongBuy: 6
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CAMT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 138.3 | -5.7% |
| Analysts Target Price | 138.3 | -5.7% |
| ValueRay Target Price | 228.5 | 55.9% |
CAMT Fundamental Data Overview January 28, 2026
P/E Forward = 44.6429
P/S = 13.4533
P/B = 11.372
P/EG = 2.9783
Revenue TTM = 485.2m USD
EBIT TTM = 27.5m USD
EBITDA TTM = 157.0m USD
Long Term Debt = 519.1m USD (from longTermDebt, last quarter)
Short Term Debt = 2.49m USD (from shortTermDebt, last fiscal year)
Debt = 519.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 319.4m USD (from netDebt column, last quarter)
Enterprise Value = 6.41b USD (6.53b + Debt 519.1m - CCE 639.5m)
Interest Coverage Ratio = 743.2 (Ebit TTM 27.5m / Interest Expense TTM 37.0k)
EV/FCF = 57.14x (Enterprise Value 6.41b / FCF TTM 112.1m)
FCF Yield = 1.75% (FCF TTM 112.1m / Enterprise Value 6.41b)
FCF Margin = 23.11% (FCF TTM 112.1m / Revenue TTM 485.2m)
Net Margin = 9.86% (Net Income TTM 47.8m / Revenue TTM 485.2m)
Gross Margin = 50.36% ((Revenue TTM 485.2m - Cost of Revenue TTM 240.9m) / Revenue TTM)
Gross Margin QoQ = 50.04% (prev 50.77%)
Tobins Q-Ratio = 5.21 (Enterprise Value 6.41b / Total Assets 1.23b)
Interest Expense / Debt = 0.01% (Interest Expense 37.0k / Debt 519.1m)
Taxrate = 9.69% (12.7m / 131.2m)
NOPAT = 24.8m (EBIT 27.5m * (1 - 9.69%))
Current Ratio = 7.58 (Total Current Assets 899.8m / Total Current Liabilities 118.7m)
Debt / Equity = 0.90 (Debt 519.1m / totalStockholderEquity, last quarter 578.0m)
Debt / EBITDA = 2.03 (Net Debt 319.4m / EBITDA 157.0m)
Debt / FCF = 2.85 (Net Debt 319.4m / FCF TTM 112.1m)
Total Stockholder Equity = 585.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.62% (Net Income 47.8m / Total Assets 1.23b)
RoE = 8.17% (Net Income TTM 47.8m / Total Stockholder Equity 585.4m)
RoCE = 2.49% (EBIT 27.5m / Capital Employed (Equity 585.4m + L.T.Debt 519.1m))
RoIC = 2.87% (NOPAT 24.8m / Invested Capital 863.8m)
WACC = 11.90% (E(6.53b)/V(7.05b) * Re(12.85%) + D(519.1m)/V(7.05b) * Rd(0.01%) * (1-Tc(0.10)))
Discount Rate = 12.85% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -3.51%
[DCF Debug] Terminal Value 69.64% ; FCFF base≈95.8m ; Y1≈118.1m ; Y5≈201.2m
Fair Price DCF = 34.14 (EV 1.88b - Net Debt 319.4m = Equity 1.56b / Shares 45.8m; r=11.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 23.14 | EPS CAGR: -44.58% | SUE: -4.0 | # QB: 0
Revenue Correlation: 91.76 | Revenue CAGR: 15.18% | SUE: 0.57 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.69 | Chg30d=-0.005 | Revisions Net=-1 | Analysts=12
EPS next Year (2026-12-31): EPS=3.32 | Chg30d=+0.001 | Revisions Net=+2 | Growth EPS=+3.8% | Growth Revenue=+5.9%